<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Olopatadine and mometasone: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Olopatadine and mometasone: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Olopatadine and mometasone: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="134840" href="/d/html/134840.html" rel="external">see "Olopatadine and mometasone: Drug information"</a> and <a class="drug drug_patient" data-topicid="134881" href="/d/html/134881.html" rel="external">see "Olopatadine and mometasone: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F57226794"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ryaltris</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F57978071"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Ryaltris</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F56529787"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Corticosteroid, Nasal</span>;</li>
<li>
<span class="list-set-name">Histamine H<sub>1</sub> Antagonist</span>;</li>
<li>
<span class="list-set-name">Histamine H<sub>1</sub> Antagonist, Second Generation</span>;</li>
<li>
<span class="list-set-name">Piperidine Derivative</span></li></ul></div>
<div class="block dop drugH1Div" id="F56546443"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="493236ef-6c7e-43e1-b6af-a9ef049ee9c4">Allergic rhinitis, seasonal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic rhinitis, seasonal:</b> Olopatadine 665 mcg and mometasone 25 mcg per spray:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Intranasal: 2 sprays <b>per nostril</b> twice daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F56546445"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F56546446"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; mometasone concentrations appear to increase with the severity of hepatic impairment; use with caution.</p></div>
<div class="block doa drugH1Div" id="F56552517"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="134840" href="/d/html/134840.html" rel="external">see "Olopatadine and mometasone: Drug information"</a>)</p>
<p style="text-indent:0em;">
<b>Note:</b> For patients with mucus crusting, rinsing with saline nasal spray before administration can remove mucus crusting and improve nasal coating (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-deShazo.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-deShazo.1'])">Ref</a></span>). If nasal obstruction is so severe that sprays cannot penetrate, consider concomitant use of an intranasal decongestant for up to 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32707227']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32707227'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="493236ef-6c7e-43e1-b6af-a9ef049ee9c4">Allergic rhinitis, seasonal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic rhinitis, seasonal: Intranasal:</b> 2 sprays (olopatadine 1,330 mcg/mometasone 50 mcg) in <b>each nostril</b> twice daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1820e284-41e2-4255-93fb-309e4d01aef5">Nonallergic rhinitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nonallergic rhinitis (off label):</b>
<b> Intranasal: </b>2 sprays (olopatadine 1,330 mcg/mometasone 50 mcg) in <b>each nostril</b> twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lieberman.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lieberman.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F56552519"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturing labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F56552520"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; drug accumulation of mometasone may increase with liver impairment.</p></div>
<div class="block adr drugH1Div" id="F56538139"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adolescents and adults. Also see individual agents.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis (1%), nasal discomfort (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Nervous system: Drowsiness</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Respiratory: Nasal mucosa ulcer, nasal septum perforation</p></div>
<div class="block coi drugH1Div" id="F56526142"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to olopatadine, mometasone, or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Untreated bacterial, fungal, or tuberculosis respiratory tract infections.</p></div>
<div class="block war drugH1Div" id="F56552508"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal suppression: When recommended doses are exceeded, or in extremely sensitive individuals, mometasone may cause hypercortisolism or suppression of the hypothalamic-pituitary-adrenal axis. Reports of hypercortisolism are rare with topical corticosteroids. Withdrawal and discontinuation of a corticosteroids should be done slowly and carefully. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do not provide the systemic steroid exposure needed to treat patients having trauma, surgery, or infections.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: Olopatadine may cause drowsiness in some patients; instruct patients to use caution when driving or operating machinery. Effects may be additive with ethanol ingestion and/or other CNS depressants.</p>
<p style="text-indent:-2em;margin-left:4em;">• Delayed wound healing: Avoid nasal corticosteroids (eg, mometasone) in patients with nasal septal ulcers, recent nasal surgery, or trauma until healing has occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions, including rash, pruritus, angioedema, and wheezing, have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunosuppression: Prolonged use of corticosteroids (eg, mometasone) may increase the incidence of secondary infections, mask acute infections (including fungal infections), prolong or exacerbate viral infections, or limit the response to vaccines. Avoid exposure to chicken pox and/or measles if not immunized.</p>
<p style="text-indent:-2em;margin-left:4em;">• Local nasal effects: May cause epistaxis, nasal ulceration, or septal perforation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Infections: Use with caution or avoid use in patients with tuberculosis (TB) infection (latent TB) or disease (active TB) of the respiratory tract; untreated systemic fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex. Do not use in untreated localized infection involving the nasal mucosa; local <i>Candida</i> infections of the nose and throat have occurred from nasal administration of mometasone.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, glaucoma, and cataracts have occurred with prolonged use of mometasone.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Avoid using higher than recommended dosages; suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, or hypercortisolism (Cushing syndrome) may occur; titrate to lowest effective dose. Reduction in growth velocity may occur when corticosteroids are administered to pediatric patients, even at recommended doses via intranasal route (monitor growth).</p></div>
<div class="block foc drugH1Div" id="F57226795"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Nasal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ryaltris: Olopatadine hydrochloride 665 mcg and mometasone furoate 25 mcg/actuation (29 g) [contains benzalkonium chloride, edetate (edta) disodium, polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F57226793"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F57229580"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Ryaltris Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">665-25 mcg/ACT (per gram): $10.30</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F57978072"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Nasal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ryaltris: Olopatadine hydrochloride 665 mcg and mometasone furoate 25 mcg/actuation (1 ea) [contains benzalkonium chloride, edetate (edta) disodium, polysorbate 80]</p></div>
<div class="block admp drugH1Div" id="F56546448"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Intranasal: Shake well prior to each use. Before first use, prime by pressing pump 6 times until a fine mist appears. If ≥14 days have elapsed since last use, the delivery system should be reprimed with 2 sprays or until a fine spray appears. Blow nose to clear nostrils before each use. Keep head tilted downward while spraying. Insert applicator into nostril keeping bottle upright, and close off the other nostril. Angle applicator slightly toward outside of the nose (towards cheek), away from the center of the nose. Breathe in through nose while pressing the pump to release spray, then breathe out through mouth. Repeat procedure to complete full dose (2 sprays each nostril). Do not blow nose for ≥15 minutes after administration. Do not spray into eyes or mouth. After each use, wipe the spray tip with a clean tissue or cloth. Discard after labeled number of doses has been used, even if bottle is not completely empty.</p></div>
<div class="block adm drugH1Div" id="F56552521"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Intranasal:</b> For intranasal administration only. Shake bottle for at least 10 seconds prior to priming, repriming, and before each use. Prime pump (press 6 times or until a fine spray appears) prior to first use. If ≥14 days (US labeling) or ≥7 days (Canadian labeling) have elapsed since last use or after cleaning a clogged nozzle, reprime the pump with 2 sprays or until fine mist appears. Blow nose to clear nostrils. Insert applicator into the nostril, tilt head slightly forward, keeping bottle upright, and close off the other nostril. Breathe in through the nose. While inhaling, press pump to release spray and exhale through the mouth. After each use, wipe the spray tip with a clean tissue or cloth and replace cap. Clogged nozzles may be removed, soaked in warm water for 15 minutes, and then rinsed and dried completely before placing back on bottle; do not try to unblock clogs with a pin or sharp object. Avoid spraying directly into the nasal septum, eyes, or mouth.</p></div>
<div class="block sts drugH1Div" id="F56552511"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store upright with the dust cap on at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Do not refrigerate or freeze. Discard after 240 medicated sprays have been used (US labeling) or within 2 months of opening (Canadian labeling).</p></div>
<div class="block usep drugH1Div" id="F56529788"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of symptoms of seasonal allergic rhinitis (FDA approved in ages ≥12 years and adults).</p></div>
<div class="block mst drugH1Div" id="F56552503"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Ryaltris may be confused with Rybelsus.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F56560285"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F56560282"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: Olopatadine (Nasal) may enhance the CNS depressant effect of CNS Depressants. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Mometasone (Nasal).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May increase the serum concentration of Corticosteroids (Nasal).<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F56552506"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Refer to individual monographs</p></div>
<div class="block mopp drugH1Div" id="F56546449"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Growth (children and adolescents); signs/symptoms of hypothalamic-pituitary-adrenal (HPA) axis suppression/adrenal insufficiency; glaucoma and/or cataracts, especially in patients with a change in vision; adverse nasal effects (eg, nasal septal perforation, nasal ulceration, irritation, epistaxis, infection).</p></div>
<div class="block pha drugH1Div" id="F56552512"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;">Olopatadine: Selective histamine H<sub>1</sub>-antagonist; olopatadine inhibits release of histamine from mast cells.</p>
<p style="text-indent:0em;">Mometasone: Mometasone may depress the formation, release, and activity of endogenous chemical mediators of inflammation (kinins, histamine, liposomal enzymes, prostaglandins). Leukocytes and macrophages may have to be present for the initiation of responses mediated by the above substances. Mometasone inhibits the margination and subsequent cell migration to the area of injury, and also reverses the dilation and increased vessel permeability in the area resulting in decreased access of cells to the sites of injury.</p></div>
<div class="block phk drugH1Div" id="F56552513"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Also see individual agents.</p>
<p style="text-indent:-2em;margin-left:2em;">Onset: Symptom improvement noted within 15 minutes following the initial dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Mean: Mometasone: 18 hours; olopatadine: 9 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Median: 1 hour.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58847627"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Ryaltris</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-deShazo.1">
<a name="deShazo.1"></a>deShazo RD, Kemp SF. Pharmacotherapy of allergic rhinitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 18, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32707227">
<a name="32707227"></a>Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. <i>J Allergy Clin Immunol</i>. 2020;146(4):721-767. doi:10.1016/j.jaci.2020.07.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olopatadine-and-mometasone-pediatric-drug-information/abstract-text/32707227/pubmed" id="32707227" target="_blank">32707227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26012297">
<a name="26012297"></a>Guo L, Sun X, Yang J, Liu J, Wang D. Clinical study of the combination therapy with intranasal antihistamine and nasal corticosteroids in the treatment of nasal obstruction of persistent non-allergic rhinitis. 2015;29(3):243-245, 251.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olopatadine-and-mometasone-pediatric-drug-information/abstract-text/26012297/pubmed" id="26012297" target="_blank">26012297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lieberman.1">
<a name="Lieberman.1"></a>Lieberman PL. Chronic nonallergic rhinitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 18, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24654314">
<a name="24654314"></a>Price D, Shah S, Bhatia S, et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. <i>J Investig Allergol Clin Immunol.</i> 2013;23(7):495-503.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olopatadine-and-mometasone-pediatric-drug-information/abstract-text/24654314/pubmed" id="24654314" target="_blank">24654314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ryaltris.1">
<a name="Ryaltris.1"></a>Ryaltris (olopatadine/mometasone) [prescribing information]. Columbus, OH: Hikma Specialty USA Inc; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ryaltris.2">
<a name="Ryaltris.2"></a>Ryaltris (olopatadine/mometasone) [product monograph]. Concord, Ontario, Canada: Glenmark Pharmaceuticals Canada Inc; September 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 134846 Version 34.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
